agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Completed · Phase 1

Conditions studied: Relapsed/Refractory Multiple Myeloma

In brief

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

Key facts

Study ID

NCT04754100

Run by

MiNK Therapeutics

People needed

13

Starts

2021-03-29

Expected to finish

2023-05-31

Last updated by the study team

2023-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida — Louisville, Kentucky, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Cincinnati Cancer Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.